Method of modulating the activity of functional immune molecules

Abstract

The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.

1 - 4 . (canceled) 
     
     
         5 . A method for producing an antibody composition, said method comprising:
 (1) introducing a vector comprising a nucleotide sequence encoding an antibody into a host cell;   (2) culturing the antibody-producing host cell; and   (3) recovering the antibody from the culture supernatant,   wherein said antibody composition comprises antibody molecules having complex-type and/or hybrid-type N-glycoside-linked sugar chain in a Fc region, wherein all of said antibody molecules have two N-glycoside-linked sugar chains in which fucose is not bound (F0).   
     
     
         6 . The method according to  claim 5 , wherein said antibody molecules comprise N-glycoside-linked sugar chains in which at least one N-acetylglucosamine is bound to a mannose at the non-reducing end of the following structure: 
       
         
           
           
               
               
           
         
       
     
     
         7 . The method according to  claim 5 , wherein said antibody molecules comprise the complex-type N-glycoside-linked sugar chains in which two N-acetylglucosamine are respectively bound to two mannoses at the non-reducing end of the following structure: 
       
         
           
           
               
               
           
         
       
     
     
         8 . The method according to  claim 5 , wherein said antibody molecules have an increased antibody dependent cellular cytotoxicity (ADCC). 
     
     
         9 . The method according to  claim 5 , wherein said antibody molecules are molecules of a human antibody, a humanized antibody, a chimeric antibody or a human CDR-grafted antibody. 
     
     
         10 . The method according to  claim 5 , wherein said antibody molecules are molecules of an IgG class antibody.